Archive for month: July, 2024

Below are the details for the admission to B.Sc Nursing, as per the information booklet-

IMPORTANT DATE

APPLICATION FEE

All candidates are required to deposit a non-refundable application fee of Rs. 1800/- (Rs. 900 for SC, ST, ST-STA category of Rajasthan state) using the procedure mentioned in the online application form (plus service charges, as applicable). The application fee is not refundable, not transferable or adjustable for any future RCA Nursing. Any request in this matter shall not be entertained.

ELIGIBILITY CRITERIA FOR ADMISSION

All residents of India fulfilling the eligibility criteria can apply to RUHS for RCA Nursing 2024 for admission to Nursing courses in different government colleges, government self-financed colleges and private colleges affiliated to Rajasthan University of Health Sciences, Jaipur (State Government Medical University), based on instructions given in this information booklet, the relevant rules of RUHS, Jaipur and directions of State Govt. / Honorable Court. For admission to B.Sc Nursing courses in colleges affiliated with RUHS, it is mandatory to appear in the B.Sc Nursing Entrance Examination 2024 [Rajasthan Centralized Admissions to Nursing Courses 2024, (RCA Nursing 2024)].

EDUCATION QUALIFICATION

A candidate must have passed the Senior Secondary School Certificate Examination (ScienceMedical group) conducted by a statutory Board at the end of 12 years of study under the 10+2 pattern of Secondary Education in all the compulsory subjects and the optional subjects of the Medical Group (Physics, Chemistry and Biology and English) or any other examination recognised by the RUHS as equivalent to above-stated qualification on the last date of submission of application form with a minimum of forty-five per cent (45%) marks and forty per cent (40%) for natural born scheduled caste and scheduled tribe candidates in aggregate of Physics, Chemistry and Biology taken together at the qualifying examination and with English as a compulsory subject in class 10+2 for being eligible for admission to B.Sc Nursing course.

AGE LIMIT

A candidate must have completed the age of 17 years but not completed 28 years in the case of females and 25 years in the case of males on or before 31st December 2024. The date of birth as recorded in the secondary education certificate will be treated as authentic.

TENTATIVE SEAT MATRIX (2024-25)

Admission for the session 2024-25 will be considered in the colleges after finalisation of the list of colleges by RUHS. Based on the B.Sc Nursing ordinance, 85% of the total seats will be filled up by the Bonafide candidates of Rajasthan, and 15% of the total seats will be filled up by the candidates on an India basis inclusive of Rajasthan as per State Government guidelines and/or Hon’ble Court directions. The percentage of female candidates shall not fall below 50% of the total seats in all categories. As per the government order dated from the academic session 2023-24, in all the nursing colleges, 100% of seats (of the intake sanctioned) shall be filled through RCA Nursing 2024. College and course-wise tentative seat matrix for the session 2024-25 will be made available at the RUHS website before choice filling.

FEE STRUCTURE

Based on the directions of the State Govt. / State Level Fee Fixation Committee, the fee structure for the B.Sc Nursing course for the session 2024-25 is as below-

The candidates are required to pay the fee as prescribed by State Government from time to time, for the course.

CHOICE FILLING

After appearing in the entrance examination, to participate in the counselling process, candidates will be required to fill choices of the course and college (in order of preference) by paying INR 550 (five hundred and fifty) as counselling fee (non-refundable). Guidelines for filling out the choices and making online payment of counselling fees will be available on the RUHS website in due course.

To view the information booklet, click the link below

The findings, published in Scientific Reports, support oral therapy as a rational treatment option, even in those with elevated HbA1c at diagnosis.

Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and relative insulin deficiency. Effective management of blood glucose levels is crucial to mitigate the risk of complications such as cardiovascular disease, neuropathy, and nephropathy. Traditionally, treatment strategies have included oral antidiabetic medications (OADs) and, in some cases, early initiation of insulin therapy.

Against the above background, Yang-Ming Lee, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan, and colleagues aimed to compare the efficacy of oral antidiabetic therapy to early insulinization on glycemic control among newly diagnosed T2D patients in real-world clinical practice.

For this purpose, the researchers conducted a retrospective cohort study at a medical center in Taiwan analyzing 1256 eligible patients from 2007 to 20177. Propensity score matching ensured that the oral antidiabetic drug (OAD) and early insulinization cohorts comprised well-balanced groups, each consisting of 94 patients. Glycemic outcomes were subsequently evaluated across both cohorts.

The researchers reported the following findings:

• Patients exclusively using OAD showed consistently lower glycated hemoglobin (HbA1c) levels at 3, 12, 24, and 36 months compared to insulin users.
• At later periods, 77.7% of OAD users achieved glycemic control versus 64.9% of insulin users, with a marginally significant difference.
• Subgroup analyses suggested a trend favoring well-controlled diabetes in the OAD group, though not statistically significant.

The findings showed that early initiation of insulin may not yield substantial improvements in glycemic control for newly diagnosed type 2 diabetes patients when compared to using OADs alone. Simply starting insulin early is inadequate; achieving optimal control requires implementing a structured insulin titration protocol and diligent self-monitoring of blood glucose levels.

“Our real-world data support considering oral antidiabetic therapy as a reasonable treatment option for newly diagnosed T2D patients, even those with increased baseline HbA1c levels,” the researchers wrote.

“Finally, while this study offers valuable insights from a specific hospital setting, its findings could be influenced by significant limitations. Thus, further investigation is needed to determine the applicability of these findings to other regions in Taiwan or different countries,” they concluded.

Reference:

Lee, Y., Lin, P. R., & Sia, H. (2024). Oral antidiabetic therapy versus early insulinization on glycemic control in newly diagnosed type 2 diabetes patients: A retrospective matched cohort study. Scientific Reports, 14(1), 1-9. https://doi.org/10.1038/s41598-024-66468-1

After nearly 13 years of follow-up, cancer survivors who adhered closely to the Mediterranean diet experienced a 32% lower risk of all-cause mortality compared to those with low adherence (hazard ratio 0.68), the researchers reported in JACC: CardioOncology.

The findings suggested the benefit of maintaining or adopting a traditional [Mediterranean diet] even after a cancer diagnosis and motivated the additional science concerning the development of dietary recommendations specifically targeted at cancer survivors.

The Mediterranean diet includes foods naturally rich in polyphenols and bioactive compounds known for their antioxidant, anti-inflammatory, and potential antitumor properties. These benefits are relevant to cancer prevention and progression and play a significant role in preventing cardiovascular mortality.

Research investigating the connections between the Mediterranean diet (MD) and mortality in cancer survivors has yielded inconclusive results. The majority of studies originate from the United States, with limited evidence available from Europe. Additionally, many studies focus on specific types of cancer survivors, which restricts the applicability of findings to the broader population of cancer survivors.

Against the above background, Marialaura Bonaccio, Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Italy, and colleagues aimed to clarify the role of a traditional MD among Italian long-term cancer survivors concerning mortality, using postdiagnosis dietary data.

Using data from the Moli-sani cohort, established in Italy between 2005 and 2010, which included 24,325 adults aged 35 years or older, the study focused on 802 participants diagnosed with cancer at baseline. These individuals provided medical records and details on cancer treatment. Dietary habits were assessed using a semiquantitative food frequency questionnaire administered by interviewers.

The study group comprised 476 women (59%) and 326 men (41%), with an average age of 63 years. Diet assessment occurred approximately 8.8 years after their cancer diagnosis.

Participants’ adherence to the Mediterranean diet was evaluated using a 9-point scale, categorized as poor (scores 0-3), average (scores 4-5), or high (scores 6-9). Those with higher adherence tended to have a higher socioeconomic status and were more likely to engage in regular physical activity compared to those with poor adherence.

The following were the key findings of the study:

• During 12.7 years of follow-up, a total of 248 deaths were recorded, including 59 attributed to cardiovascular causes and 140 from cancer. Analyses were adjusted for age, sex, energy intake, education, smoking status, physical activity, and hormone replacement therapy, among other factors.
• Each 2-point increment in the Mediterranean diet score was associated with a 16% lower risk of all-cause mortality (HR 0.84) and a 31% lower risk of cardiovascular death (HR 0.69).
• Survivors with high adherence to the diet had a 32% lower risk of all-cause mortality compared to those with poor adherence (HR 0.68).
• High adherence to the diet was not significantly associated with lower cancer mortality (HR 0.79).

“Our results indicate that continuing or adopting a traditional Mediterranean diet following a cancer diagnosis could offer benefits,” the researchers concluded. “This underscores the need for further research to develop tailored dietary guidelines for cancer survivors.”

Reference:

Bonaccio M, et al “Mediterranean diet is associated with lower all-cause and cardiovascular mortality among long-term cancer survivors” JACC CardioOncol 2024; DOI: 10.1016/j.jaccao.2024.05.012.